Latest Stock/Share Market Updates | Corporate News | Announcements | BSE
Notices Media Release Trading Holidays BSEPlus Contact Us
हिन्दी     मराठी     ગુજરાતી


Latest Corporate Announcements

Announcement Type :   Search By :    
Security Name
Category
Date Calendar
To Date Calendar
Disclaimer  Next >>
   
Security Code : 532488    Company : DIVI'S LABORATORIES LTD.
07 Jun 2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011Insider Trading / SASTDownload PDF
  Exchange Disseminated Time     07/06/2017 15:29:35
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Reliance Nippon Life Asset Management Ltd
 
26 May 2017
Board recommends DividendCorp. ActionDownload PDF
  Exchange Disseminated Time     26/05/2017 18:26:14
Divis Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2017, inter alia, has recommended dividend @ 500% i.e Rs. 10/- per equity share of face value Rs. 2/- each for the year ended March 31, 2017, subject to approval of the member in ensuing Annual General Meeting (AGM). The dividend on Equity Shares, shall be paid within 30 (thirty) days from the conclusion of the AGM, the date of which will be intimated in due course.
 
  Financial Results For The Quarter And Year Ended 31St March, 2017ResultDownload PDF
  Exchange Received Time  26/05/2017 18:07:55         Exchange Disseminated Time   26/05/2017 18:08:01              Time Taken   00:00:06
Further to our letter dated 15th May, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Friday, 26th May 2017 has approved the Audited Financial Results for the quarter and year ended 31st March, 2017. Board has recommended dividend @ 500% i.e Rs. 10/- per equity share of face value Rs. 2/- each for the year ended 31st March 2017, subject to approval of the member in ensuing Annual General Meeting (AGM). ....
15 May 2017
  Board to consider FY17 Results & Dividend on May 26, 2017Corp. ActionDownload PDF
  Exchange Disseminated Time     15/05/2017 12:29:44
Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on May 26, 2017, inter alia, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2017 and to recommend dividend, if any, on Equity Shares for the financial year 2016-17.

Further, the Trading Window for dealing in securities of the Company shall remain closed for insiders ....
  Board Meeting On 05 26,2017Board MeetingDownload PDF
  Exchange Received Time  15/05/2017 12:24:06         Exchange Disseminated Time   15/05/2017 12:24:15              Time Taken   00:00:09
Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Friday, the 26th day of May 2017, inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended 31st March 2017 and to recommend dividend, if any, on Equity Shares for the financial year 2016-17. We further inform you that the Trading Window for dealing in securities of the Company shall remain closed ....
22 Apr 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  22/04/2017 11:33:39         Exchange Disseminated Time   22/04/2017 11:33:44              Time Taken   00:00:05
Further to our earlier communication dated 8th April, 2017 to the Stock Exchanges, we wish to update that the US-FDA has issued a Warning Letter for the company's Unit-II at Visakhapatnam. Divi's Laboratories responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed. As part of our commitments, we have also provided periodic updates to the US-FDA. In the Import Alert issued, ....
08 Apr 2017
UpdatesCompany UpdateDownload PDF
  Exchange Received Time  08/04/2017 15:00:33         Exchange Disseminated Time   08/04/2017 15:00:40              Time Taken   00:00:07
Further to our earlier communication dated 22nd March, 2017 to the Stock Exchanges, we wish to update that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from the Import Alert issued under clauses 66-40 & 99-32 of the FDA regulations.
 
07 Apr 2017
Compliance Certificate For Half Year Ended 31St March 2017  Download PDF
  Exchange Received Time  07/04/2017 16:55:13         Exchange Disseminated Time   07/04/2017 16:55:20              Time Taken   00:00:07
Please find enclosed Compliance Certificate as required under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended 31st March 2017
 
Shareholding for the Period Ended March 31, 2017Company Update 
  Exchange Disseminated Time     07/04/2017 09:46:15
Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here
 
Compliance Certificate For The Period Ended 31St March 2017 Download PDF
  Exchange Received Time  07/04/2017 09:18:32         Exchange Disseminated Time   07/04/2017 09:18:39              Time Taken   00:00:07
We enclose herewith Compliance Certificate certifying compliance with the requirements of sub-regulation (2), from the Company and the Registrar and Share Transfer Agent for half year ended 31st March 2017.
 
  Statement Of Investor Complaints For The Quarter Ended 31St March 2017 Download PDF
  Exchange Received Time  07/04/2017 09:14:44         Exchange Disseminated Time   07/04/2017 09:14:47              Time Taken   00:00:03
In compliance with Regulation 13 (3) of SEBI (LODR) Regulations, 2015, please find below the statement of investors complaints for the quarter ended 31st March, 2017: S.No. Particulars Number 1 Number of complaints pending at the beginning of the quarter Nil 2 Number of complaints received during the quarter 3 3 Number of complaints disposed of during ....
24 Mar 2017
Intimation Of Schedule Of Conference Call (11.00 Am IST, March 27, 2017) Download PDF
  Exchange Received Time  24/03/2017 18:13:34         Exchange Disseminated Time   24/03/2017 18:13:39              Time Taken   00:00:05
Notice is hereby given that, the Analyst/ Investor Conference call is scheduled at 11.00 am IST on March 27, 2017 where Company's Management will discuss and answer questions from participants w.r.t Import Alert received by the Company from US-FDA. The operator will provide instructions on asking questions before the call. A transcript of this conference call will be available on the Company's website www.divislabs.com. Details of conference dial-in information is enclosed herewith.
 
22 Mar 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  22/03/2017 16:40:32         Exchange Disseminated Time   22/03/2017 16:40:38              Time Taken   00:00:06
Further to our earlier communication dated 21st March, 2017 to the Stock Exchanges, we wish to update that the Import Alert by US-FDA for the products manufactured at the company's Unit-II at Visakhapatnam was issued under two clauses 66-40 & 99-32 of the FDA regulations. As mentioned earlier, the Agency has exempted the following products from the Import Alert: 1. Levetiracetam 2. Gabapentin 3. Lamotrigine 4. Capecitabine 5. Naproxen sodium ....
21 Mar 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  21/03/2017 08:56:06         Exchange Disseminated Time   21/03/2017 08:56:07              Time Taken   00:00:01
Further to our earlier communication to Stock Exchanges, we wish to state that US-FDA has issued an Import Alert 66-40 on 20th March 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. The Agency has exempted the following products from the Import Alert: 1. Levetiracetam 2. Gabapentin 3. Lamotrigine 4. Capecitabine 5. Naproxen sodium 6. Raltegravir potassium 7. Atovaquone 8. Chloropurine 9. BOC ....
04 Feb 2017
Announces Q3 results (Standalone), Limited Review Report (Standalone) & Results Press Release for the Quarter ended December 31, 2016ResultDownload PDF
  Exchange Disseminated Time     04/02/2017 11:53:21
Divis Laboratories Ltd has announced the following Unaudited Standalone results for the Quarter ended December 31, 2016

The Company has posted a net profit of Rs. 2683.20 million for the quarter ended December 31, 2016 as compared to Rs. 2467.60 million for the quarter ended December 31, 2015. Total Income has increased from Rs. 8739.80 million for the quarter ended December 31, 2015 to Rs. 9949.50 million for the quarter ended December 31, 2016.
 
23 Jan 2017
  Q3 results on Feb 04, 2017Board MeetingDownload PDF
  Exchange Disseminated Time     23/01/2017 10:14:06
Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on February 04, 2017, inter alia, to consider and approve, the un-audited financial results for the quarter and nine months ended December 31, 2016(Q3).

Further, the Trading Window for dealing in securities of the Company shall remain closed for insiders of the Company from January 28, 2017 to February 06, 2017 (both days inclusive) ....
16 Jan 2017
Shareholding for the Period Ended December 31, 2016Company Update 
  Exchange Disseminated Time     16/01/2017 16:18:48
Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here
 
10 Jan 2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016Company UpdateDownload PDF
  Exchange Disseminated Time     10/01/2017 11:20:52
Divis Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 
09 Jan 2017
Update on US-FDA inspection of Unit-II at VisakhapatnamCompany UpdateDownload PDF
  Exchange Disseminated Time     09/01/2017 09:57:21
Divis Laboratories Ltd has informed BSE that the company has already filed its detailed response to the ‘Form 483’ observations of the US-FDA within the time permitted.
 
23 Dec 2016
Clarifies on News ItemCompany UpdateDownload PDF
  Exchange Disseminated Time     23/12/2016 16:03:27
With reference to news appeared in CNBC TV 18 dated December 23, 2016 quoting "Emkay says on Vizag 483 observation:

1. proper control not being exercised over computer system
2. facility equipments not maintained to ensure purity quality strength
3. documentation and records not maintained or inaccurate falsified "

Divis Laboratories Ltd has submitted to BSE a copy of Clarification is enclosed.
 

Disclaimer Next >>